Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Topical Sirolimus (NPC-12G) vs Oral Rapamune
NCT03972462Phase 1Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirolimus in facial angiofibroma and tuberous sclerosis complex (TSC) (2 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to 48 Hours, Maximum Observed Plasma Concentration at 48 hours and 1 more. Started May 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
facial angiofibromatuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT03972462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972462.